Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V.
Rubinstein MM, et al. Among authors: cohen s.
Gynecol Oncol. 2023 Feb;169:64-69. doi: 10.1016/j.ygyno.2022.11.028. Epub 2022 Dec 10.
Gynecol Oncol. 2023.
PMID: 36512912
Free PMC article.
Clinical Trial.